Case Report: Omalizumab Successfully Treated Recalcitrant Bullous Pemphigoid in an Elderly Patient with Multiple Comorbidities

Liu, Jue; Xiang, Tingkai; Wang, Wei; Bu, Zhangyu

doi:10.2147/ccid.s373682

Cited by 3 publications

(1 citation statement)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Since then, omalizumab has been used for BP every year from 2014 to the present, and the number of users has increased with time, with Velin et al 49 Alexandre et al 50 and Liu et al 51 in 2022 describing a total of 16 patients treated with omalizumab for BP patients, the largest number of patients with this treatment in 1 year. The majority of these patients had significant clinical outcomes, greatly increasing the number of cases documented in the literature and further confirming the effectiveness of omalizumab in treating BP.…”

Section: Discussionmentioning

confidence: 99%

Research progress of omalizumab in the treatment of bullous pemphigoid

Ling

Shou

Lou

et al. 2023

The Journal of Dermatology

View full text Add to dashboard Cite

Bullous pemphigoid (BP) is an autoimmune blistering disease associated with anti-BP180 and anti-BP230 antibodies. The pathogenic action mechanism of immunoglobulin E (IgE) antibodies in BP has been studied since the 1970s, and IgE antibodies have gradually been confirmed as being important in BP; therefore, anti-IgE therapy may be a new option for the treatment of BP. Omalizumab, as an IgE monoclonal antibody, has been increasingly used clinically to treat BP in recent years. Here, we collected 35 papers investigating omalizumab for BP treatment in a total of 83 patients, and the vast majority of patients showed varying degrees of improvement after treatment, except for a small number of patients with poor clinical outcomes. The patients were then divided into three groups according to dosing frequency and number of doses. Statistical analysis indicated that dosing frequency had little effect on clinical efficacy. While the groups with different numbers of doses were evaluated, the results concluded that clinical efficacy was affected by the number of doses, but there was no positive correlation between the number of doses and clinical efficacy.

show abstract

Section: Discussionmentioning

confidence: 99%

Research progress of omalizumab in the treatment of bullous pemphigoid

Ling

Shou

Lou

et al. 2023

The Journal of Dermatology

View full text Add to dashboard Cite

show abstract

Multiple drugs

2022

Reactions Weekly

View full text Add to dashboard Cite

Omalizumab and Dupilumab for the Treatment of Bullous Pemphigoid: A Systematic Review

Granados-Betancort,

Sánchez-Díaz,

Muñoz-Barba

et al. 2024

JCM

View full text Add to dashboard Cite

Background: Bullous pemphigoid (BP) is an autoimmune disease characterized by the appearance of very pruritic subepidermal blisters. It appears mostly in the elderly and is associated with multiple comorbidities, which makes its management and treatment difficult. The purpose of this systematic review is to compile current information on published cases of BP treated with omalizumab (omalizumab) and dupilumab (dupilumab) in order to obtain information on clinical efficacy and safety data available. Methods: A literature search of all cases of BP treated with omalizumab/dupilumab published in the literature up to January 2024 was performed using the Pubmed database. After an exhaustive search, a total of 61 studies encompassing 886 patients met the inclusion criteria and were included in the review. Results: The majority of patients with BP treated with omalizumab/dupilumab presented a significant improvement in symptomatology, being very safe drugs with minimal side effects. The main limitation of the presented review is the quality of the included studies, most of them being case series or individual cases. The development of studies with a higher level of scientific evidence in the near future would be of great interest. Conclusions: Both omalizumab and dupilumab appear to be effective options for treating BP in patients refractory to other pharmacological therapies. They are drugs with a good safety profile and the adverse reactions associated with their use are infrequent and generally mild.

show abstract

Case Report: Omalizumab Successfully Treated Recalcitrant Bullous Pemphigoid in an Elderly Patient with Multiple Comorbidities

Cited by 3 publications

References 21 publications

Research progress of omalizumab in the treatment of bullous pemphigoid

Research progress of omalizumab in the treatment of bullous pemphigoid

Multiple drugs

Omalizumab and Dupilumab for the Treatment of Bullous Pemphigoid: A Systematic Review

Contact Info

Product

Resources

About